Novo Nordisk shares slide 6% after Wegovy pill sales miss despite earnings beat

Novo Nordisk reported second‑quarter results that beat both revenue and profit forecasts, posting a profit of $5.15 billion.

The company’s oral Wegovy obesity pill generated $496 million in sales, roughly 2% below analyst consensus, a shortfall the firm linked to inventory destocking.

By contrast, the injectable Wegovy product exceeded expectations, delivering about $3 billion in sales, a modest 2% upside.

The mixed performance pushed Novo’s share price down 6% to $44.26 in afternoon trading, as investors focused on the pill’s miss and softer U.S. injectable sales.